Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TX103 |
Synonyms | |
Therapy Description |
TX103 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially enhances antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2062)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TX103 | TX 103|TX-103 | TX103 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially enhances antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2062)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06482905 | Phase I | TX103 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | Recruiting | USA | 1 |